| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 727.10M | 757.10M | 802.50M | 743.60M | 615.80M |
| Gross Profit | 280.80M | 109.30M | 108.10M | 269.70M | 225.70M |
| EBITDA | 179.80M | 124.00M | 201.70M | 186.60M | 167.70M |
| Net Income | 54.90M | 20.00M | 85.60M | 73.70M | 59.50M |
Balance Sheet | |||||
| Total Assets | 1.05B | 1.07B | 1.14B | 1.17B | 1.07B |
| Cash, Cash Equivalents and Short-Term Investments | 25.20M | 19.10M | 45.20M | 37.20M | 39.30M |
| Total Debt | 190.80M | 150.90M | 96.90M | 136.60M | 156.20M |
| Total Liabilities | 411.70M | 397.50M | 344.40M | 385.70M | 384.40M |
| Stockholders Equity | 640.20M | 668.10M | 790.80M | 780.90M | 684.70M |
Cash Flow | |||||
| Free Cash Flow | 58.90M | 82.50M | 109.20M | 70.10M | 87.10M |
| Operating Cash Flow | 135.30M | 152.60M | 191.60M | 137.10M | 139.10M |
| Investing Cash Flow | -56.00M | -112.80M | -71.20M | -62.30M | -104.80M |
| Financing Cash Flow | -71.00M | -67.60M | -110.20M | -82.80M | -30.30M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | £1.82B | 15.43 | 33.12% | 1.01% | 24.42% | 103.25% | |
70 Outperform | £176.33M | 10.69 | 6.13% | 1.02% | 14.49% | 76.33% | |
65 Neutral | £110.87M | 7.63 | 3.83% | 6.69% | -13.30% | -60.03% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
62 Neutral | £1.08B | 22.48 | 8.58% | 3.30% | -6.95% | -52.08% | |
62 Neutral | £534.19M | 28.89 | 8.04% | 4.87% | -7.30% | -59.71% | |
61 Neutral | £4.81B | 30.76 | 13.88% | 2.46% | 0.10% | -15.33% |
Bodycote plc has launched a new share buyback programme of up to £80 million, to be completed by the end of 2027, signalling confidence in its strong balance sheet and a disciplined approach to capital allocation. The programme will be executed in two £40 million tranches, with Barclays Bank PLC mandated to repurchase and cancel up to 12,301,205 ordinary shares under current authority, reducing the company’s share capital and potentially enhancing earnings per share and shareholder value.
Under an arrangement with Barclays, the bank will act as riskless principal in purchasing Bodycote shares in compliance with UK Listing Rules and shareholder authorities, including during closed periods where trades will be conducted independently of the company. All repurchased shares will be cancelled, underlining that the sole purpose of the initiative is capital reduction rather than holding treasury stock, reinforcing Bodycote’s capital return strategy for investors.
The most recent analyst rating on (GB:BOY) stock is a Hold with a £829.00 price target. To see the full list of analyst forecasts on Bodycote stock, see the GB:BOY Stock Forecast page.
Bodycote plc has confirmed that, as of 27 February 2026, it has 172,762,590 ordinary shares in issue, each carrying voting rights, with none held in treasury. This disclosure clarifies the company’s current share capital structure for investors and maintains compliance with the Financial Conduct Authority’s transparency requirements.
The stated figure will serve as the denominator for shareholders when calculating whether their holdings trigger disclosure thresholds under U.K. rules on significant shareholdings. The announcement helps ensure accurate reporting of ownership changes, supporting market transparency and providing a clear reference point for institutional and retail investors monitoring their positions in Bodycote.
The most recent analyst rating on (GB:BOY) stock is a Hold with a £829.00 price target. To see the full list of analyst forecasts on Bodycote stock, see the GB:BOY Stock Forecast page.